CTOs on the Move

Asklepios BioPharmaceutical

www.askbio.com

 
Asklepios BioPharmaceutical, Inc. (AskBio) is a leading clinical-stage adeno-associated virus (AAV) gene therapy company dedicated to improving the lives of patients with rare diseases and other genetic disorders.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.askbio.com
  • 20 T.W. Alexander Drive Suite 110
    Research Triangle Park, NC USA 27709
  • Phone: 919.561.6210

Executives

Name Title Contact Details

Funding

Asklepios BioPharmaceutical raised $235M on 04/11/2019

Similar Companies

Brightseed

Brightseed enables a healthier future by illuminating and activating the connections between people and plants. Despite centuries of wisdom proving the critical roles plants play in supporting our health, the majority of active compounds in the plant kingdom remain unexplored. Our artificial intelligence, Forager®, reveals powerful compounds hidden in nature and our team scientifically validates their impact.

Viela Bio

Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.

Pharmaceutical Services Corp

Pharmaceutical Services Corp is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lathrop

Lathrop is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DermTech

Welcome to the new era of skin cancer detection. At DermTech we bring precision to the practice of dermatology through non-invasive genomic testing. And we developed the Smart Sticker that`s making it possible. The DermTech Smart Sticker collects an RNA sample by painlessly lifting skin cells off the entire surface of a mole. This gives doctors the power to diagnose skin cancer in its earliest stages—without a scalpel, without cutting, without scarring. After collection, stickers are sent to our team of scientists in the Gene Lab, the only commercial lab to extract nucleic acids and other proteins from non-invasive skin samples. We amplify RNA molecules to detect two specific genes that are highly predictive of melanoma—PRAME and LINC00518. This process provides 10,000x greater precision in the ability to detect melanoma. We have created the step before the scalpel—a tool doctors have never had before. Now the doctor has the choice of using a non-invasive, highly accurate test to check for melanoma without cutting. And this is just the beginning. We are developing other tests using the Smart Sticker that will further advance early disease detection.